First-in-class drug ‘effective’ in hypertrophic cardiomyopathy

The results show the benefit of disease-targeted therapy, researchers say
Medicom Staff writer
Histologogy pic - cardiac myocytes

AusDoc brings you the latest news from the European Society of Cardiology Congress 2020.

Mavacamten, a first-in-class cardiac myosin inhibitor, improves a range of outcomes in patients with obstructive hypertrophic cardiomyopathy, trial results show.

Results of the EXPLORER-HCM trial, presented at the European Society of Cardiology’s virtual congress (ESC 2020) this week compared outcomes of 123 people randomised to mavacamten (starting at 5mg) with 128 randomised to placebo over 30 weeks.

All participants had hypertrophic cardiomyopathy with a left ventricular outflow tract (LVOT) obstruction gradient of 50mmHg or more and were of New York Heart Association (NYHA) functional class II-III.